|Published (Last):||22 October 2011|
|PDF File Size:||6.70 Mb|
|ePub File Size:||12.48 Mb|
|Price:||Free* [*Free Regsitration Required]|
Medullary thyroid carcinoma: from definition to genetic bases. Medullary thyroid carcinoma MTC is a rare malignant tumor arising from thyroid C cells. Different clinical forms of MTC, mainly those hereditary forms, are related to mutations in the RET proto-oncogene, which result in a constitutive activation of the transmembrane tyrosine kinase receptor. The distinction between sporadic and familial forms is of extreme clinical relevance because of differences in prognosis and the need for family screening, genetic counseling and close clinical follow up in the inherited forms.
Genetic study of the proto-oncogene RET allows the identification of asymptomatic carriers of RET mutations, leading to an early and effective surgical management reducing the morbidity and mortality associated with this disease. Erdogan e cols. Em , Mulligan e cols. O protooncogene RET humano foi inteiramente clonado por Pasini e cols. Entretanto, trabalhos de Gimm e cols. Ainda, recentemente, Wiench e cols. Busnardo B, De Vido D. The epidemiology and etiology of differentiated thyroid carcinoma.
Biomed Pharmacother ; Multiple endocrine neoplasia type 2. Clinical features and screening. Endocrinol Metab Clin North Am ; Medullary thyroid carcinoma.
A fundamental and clinical text. Philadelphia: Lippincott-Raven Publishers, Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer ; Current approaches and perspectives in the therapy of medullary thyroid carcinoma.
Medullary solid carcinoma of the thyroid - a clinicopathologic entity. J Clin Endocrinol Metab ; J Pathol Bacteriol ; Medicine Baltimore ; Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas.
A possible regulatory defect in the differentiation of chromaffin tissue. N Engl J Med ; Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid: a syndrome. Hazard JB. Am J Pathol ; The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA ; In: Medeiros-Neto G. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma.
Am J Med ; Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol ; Ponder BAJ. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res ;59 suppl. Rio de Janeiro: Guanabara-Koogan, Eng C, Mulligan LM.
Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours and Hirschsprung disease. Hum Mutat ; Multiple endocrine neoplasia type 2: management of patients and subjects at risk. Horm Res ; The two-mutational-event theory in medullary thyroid carcinoma.
Am J Hum Genet ; Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma. World J Surg ; Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay.
N Eng J Med ; Arq Bras Endocrinol Metab ; Incidental detection of familial medullary thyroid carcinoma by calcitonin screening for nodular thyroid disease. Eur J Endocrinol ; Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Omeprazole: calcitonin stimulation test for the diagnosis follow-up and family screening in medullary thyroid carcinoma. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
Horm Metab Res ; Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs. Clin Chem ; Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet ; Pathology of the thyroid disease. In: Sternberg SS. Diagnostic surgical pathology.
The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung disease. Almeida, AAL. Characterization of the clinical features of five families with hereditary primary cutaneous lichen amyloidosis and multiple endocrine neoplasia type 2. Henry Ford Hosp Med J ; Maciel RMB.
In: Wajchenberg BL, editor. Immunohistochemistry of medullary thyroid carcinoma and C-cell hyperplasia by an affinity-purified anti-human calcitonin antiserum. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma.
Rays ; New tracers for the imaging of the medullary thyroid carcinoma. Nucl Med Commun ; Delellis RA. C-cell hyperplasia: a current perspective. Adv Anat Pathol ; Chan, JKC.
Tumors of the thyroid and parathyroid glands. In: Fletcher CDM, editor. Diagnostic histopathology of tumors. London: Churchill Livingstone, Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in patients.
Clin Endocrinol Oxf ; Cell ; A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome Nature ; Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Human ret proto-oncogene mapped to chromosome 10q Oncogene ;
Thyroid cancer, medullary
This table lists symptoms that people with this disease may have. For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. The HPO collects information on symptoms that have been described in medical resources. The HPO is updated regularly.
Medullary thyroid carcinoma.
Skip to search form Skip to main content You are currently offline. Some features of the site may not work correctly. DOI: Medullary thyroid carcinoma is characterized by specific histological properties and by the production of a tumor marker called calcitonin. View via Publisher.
Debora R. Siqueira 1. Marco A. Kulcsar 2.